サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1451268

スタチン市場レポート：タイプ別、治療領域別、薬剤クラス別、用途別、流通別、地域別、2024-2032

Statin Market Report by Type, Therapeutic Area, Drug Class, Application, Distribution, and Region 2024-2032
出版日: | 発行: IMARC | ページ情報: 英文 144 Pages | 納期: 2～3営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=157.14円
スタチン市場レポート：タイプ別、治療領域別、薬剤クラス別、用途別、流通別、地域別、2024-2032
出版日: 2024年03月02日
発行: IMARC
ページ情報: 英文 144 Pages
納期: 2～3営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

世界のスタチン市場規模は2023年に154億米ドルに達しました。今後、IMARC Groupは、市場は2032年までに200億米ドルに達し、2024～2032年の成長率（CAGR）は2.9%になると予測しています。同市場は、世界の心血管疾患と高コレステロール血症の有病率の増加、ヘルスケアインフラの拡大、コレステロール低下薬への保険適用が可能であることなどが世界の需要を後押しし、着実な成長を遂げています。

スタチン市場の分析

市場の成長と規模：世界市場は、心血管疾患の有病率の増加を主な要因として、著しい成長を遂げています。コレステロール低下薬に対する需要の高まりとともに、心臓の健康を管理するための効果的な治療法に対する認識とニーズの高まりを反映して、市場規模は拡大しています。

技術の進歩：特に個別化医療の分野における技術開拓がスタチン市場に革命をもたらしています。ゲノミクスとバイオインフォマティクスの進歩は、より個別化された治療アプローチを可能にし、スタチンの有効性を向上させ、副作用のリスクを低減しているため、市場の成長を促進しています。

産業用途：スタチンは主に、LDLコレステロール値を低下させることによる心血管疾患の予防と治療のためにヘルスケア業界で使用されています。その用途は、特に心臓病のリスクが高い人々の心臓の健康管理に不可欠となっています。

主な市場動向：スタチン市場の顕著な動向は、個人の遺伝子プロファイルに合わせた治療を行う精密医療へのシフトです。さらに、予防ヘルスケア対策への注目が高まっており、これが心血管疾患の予防薬としてのスタチン需要を牽引しています。

地理的動向：スタチンの需要は、高齢化が進み、心臓病の生活習慣関連危険因子が蔓延している地域で特に高いです。北米や欧州などの市場開拓地域が現在市場を独占しているが、新興経済諸国では健康意識の高まりやヘルスケアインフラの改善により需要が拡大しています。

競合情勢：世界市場には複数の主要プレーヤーが存在し、技術革新、製品開拓、マーケティング戦略によって競合が繰り広げられています。また、スタチン治療へのアクセス性と有効性を高めるために、製薬企業とヘルスケアプロバイダーとの協業も進んでいます。

課題と機会：市場の大きな課題のひとつは、スタチン使用に伴う副作用への対応であり、これは患者のコンプライアンスに影響を及ぼす可能性があります。しかし、この課題は副作用の少ない新しいスタチン製剤を開発する好機でもあります。さらに、世界の心血管疾患の罹患率の増加は、市場拡大の大きなチャンスとなっています。

スタチン市場の動向：

心血管疾患の増加

心血管疾患（CVDs）の罹患率の上昇が世界市場を大きく牽引しています。コレステロール低下作用で知られるスタチンは、CVDの管理と予防に重要な役割を果たしています。この健康負担の増大は、高LDLコレステロールなどの危険因子に対する意識の高まりと積極的な管理につながっています。したがって、このことは市場にプラスの影響を与えています。その結果、患者数の増加と予防ヘルスケアの重視の高まりの両方によって、スタチンに対する需要が高まっています。この動向は、人口の高齢化と生活習慣に関連した危険因子を抱える地域で特に顕著であり、スタチンを心血管の治療と健康管理における重要な要素にしています。

個別化医療の進展

世界市場は、個別化医療における著しい進歩によっても推進されています。個別化医療（精密医療）とは、患者一人ひとりの特性に合わせた医療を行うことであり、スタチンの場合、スタチンに対する個人の反応性に影響を及ぼす遺伝的要因を考慮する必要があります。さらに、調査により、遺伝的変異がスタチンに対する効果や副作用のリスクの両面で人の反応に影響を与えることが示されています。その結果、スタチン治療を最適化する個別化治療計画の開発にますます焦点が当てられています。さらに、ヘルスケアにおけるゲノミクスとバイオインフォマティクスの統合は、このように市場の革新と成長を促進する重要な要因となっています。

政府の取り組みとヘルスケア政策

政府のイニシアティブとヘルスケア政策は、世界市場に大きな影響を与えます。世界中の多くの政府が、増加する心臓病の発症率と闘うための政策やプログラムを実施しています。こうした取り組みには、第一選択薬としてスタチンの使用を推奨するコレステロール管理に関するガイドラインがしばしば含まれています。さらに、政府やヘルスケア機関は、心臓病が発生してから治療するよりも予防する方が費用対効果が高いことを認識し、予防医療対策にますます重点を置くようになっています。このような焦点の変化は、コレステロール管理の重要性に対する認識を高める公衆衛生キャンペーンへの資金提供の増加につながり、スタチンに対する需要を促進しています。さらに、国内および国際的な治療ガイドラインにスタチンが盛り込まれたことで、心血管系の健康管理におけるスタチンの重要性がさらに強調され、臨床現場での採用が後押しされています。

目次

第1章 序文

第2章 調査範囲と調査手法

  • 調査目的
  • 利害関係者
  • データソース
    • 一次情報
    • 二次情報
  • 市場推定
    • ボトムアップアプローチ
    • トップダウンアプローチ
  • 調査手法

第3章 エグゼクティブサマリー

第4章 イントロダクション

  • 概要
  • 主要業界動向

第5章 スタチンの世界市場

  • 市場概要
  • 市場実績
  • COVID-19の影響
  • 市場予測

第6章 市場内訳：タイプ別

  • 合成スタチン
    • 市場動向
    • 市場予測
  • 天然スタチン
    • 市場動向
    • 市場予測

第7章 市場内訳：治療領域別

  • 心血管疾患
    • 市場動向
    • 市場予測
  • 肥満症
    • 市場動向
    • 市場予測
  • 炎症性疾患
    • 市場動向
    • 市場予測
  • その他
    • 市場動向
    • 市場予測

第8章 市場内訳：薬剤クラス別

  • アトルバスタチン
    • 市場動向
    • 市場予測
  • フルバスタチン
    • 市場動向
    • 市場予測
  • ロバスタチン
    • 市場動向
    • 市場予測
  • プラバスタチン
    • 市場動向
    • 市場予測
  • シンバスタチン
    • 市場動向
    • 市場予測
  • その他
    • 市場動向
    • 市場予測

第9章 市場内訳：用途別

  • 脂質異常症
    • 市場動向
    • 市場予測
  • その他
    • 市場動向
    • 市場予測

第10章 市場内訳：流通別

  • 病院
    • 市場動向
    • 市場予測
  • 診療所
    • 市場動向
    • 市場予測
  • その他
    • 市場動向
    • 市場予測

第11章 市場内訳：地域別

  • 北米
    • 米国
      • 市場動向
      • 市場予測
    • カナダ
      • 市場動向
      • 市場予測
  • 欧州
    • ドイツ
      • 市場動向
      • 市場予測
    • フランス
      • 市場動向
      • 市場予測
    • 英国
      • 市場動向
      • 市場予測
    • イタリア
      • 市場動向
      • 市場予測
    • スペイン
      • 市場動向
      • 市場予測
    • ロシア
      • 市場動向
      • 市場予測
    • その他
      • 市場動向
      • 市場予測
  • アジア太平洋
    • 中国
      • 市場動向
      • 市場予測
    • 日本
      • 市場動向
      • 市場予測
    • インド
      • 市場動向
      • 市場予測
    • 韓国
      • 市場動向
      • 市場予測
    • オーストラリア
      • 市場動向
      • 市場予測
    • インドネシア
      • 市場動向
      • 市場予測
    • その他
      • 市場動向
      • 市場予測
  • ラテンアメリカ
    • ブラジル
      • 市場動向
      • 市場予測
    • メキシコ
      • 市場動向
      • 市場予測
    • その他
      • 市場動向
      • 市場予測
  • 中東・アフリカ地域
    • 市場動向
    • 市場内訳：国別
    • 市場予測

第12章 SWOT分析

  • 概要
  • 強み
  • 弱み
  • 機会
  • 脅威

第13章 バリューチェーン分析

第14章 ポーターのファイブフォース分析

  • 概要
  • 買い手の交渉力
  • 供給企業の交渉力
  • 競合の程度
  • 新規参入業者の脅威
  • 代替品の脅威

第15章 価格指標

第16章 競合情勢

  • 市場構造
  • 主要企業
  • 主要企業のプロファイル
    • Abbott
    • AstraZeneca
    • Aurobindo Pharma
    • Biocon
    • GlaxoSmithKline
    • Merck & Co.
    • Novartis
    • Pfizer
図表

List of Figures

  • Figure 1: Global: Statin Market: Major Drivers and Challenges
  • Figure 2: Global: Statin Market: Sales Value (in Billion US$), 2018-2023
  • Figure 3: Global: Statin Market: Breakup by Type (in %), 2023
  • Figure 4: Global: Statin Market: Breakup by Therapeutic Area (in %), 2023
  • Figure 5: Global: Statin Market: Breakup by Drug Class (in %), 2023
  • Figure 6: Global: Statin Market: Breakup by Application (in %), 2023
  • Figure 7: Global: Statin Market: Breakup by Distribution (in %), 2023
  • Figure 8: Global: Statin Market: Breakup by Region (in %), 2023
  • Figure 9: Global: Statin Market Forecast: Sales Value (in Billion US$), 2024-2032
  • Figure 10: Global: Statin (Synthetic Statins) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 11: Global: Statin (Synthetic Statins) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 12: Global: Statin (Natural Statins) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 13: Global: Statin (Natural Statins) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 14: Global: Statin (Cardiovascular Disorders) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 15: Global: Statin (Cardiovascular Disorders) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 16: Global: Statin (Obesity) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 17: Global: Statin (Obesity) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 18: Global: Statin (Inflammatory disorders) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 19: Global: Statin (Inflammatory disorders) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 20: Global: Statin (Other Therapeutic Areas) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 21: Global: Statin (Other Therapeutic Areas) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 22: Global: Statin (Atorvastatin) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 23: Global: Statin (Atorvastatin) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 24: Global: Statin (Fluvastatin) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 25: Global: Statin (Fluvastatin) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 26: Global: Statin (Lovastatin) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 27: Global: Statin (Lovastatin) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 28: Global: Statin (Pravastatin) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 29: Global: Statin (Pravastatin) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 30: Global: Statin (Simvastatin) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 31: Global: Statin (Simvastatin) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 32: Global: Statin (Other Drug Classes) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 33: Global: Statin (Other Drug Classes) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 34: Global: Statin (Dyslipidemia) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 35: Global: Statin (Dyslipidemia) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 36: Global: Statin (Other Applications) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 37: Global: Statin (Other Applications) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 38: Global: Statin (Hospitals) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 39: Global: Statin (Hospitals) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 40: Global: Statin (Clinics) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 41: Global: Statin (Clinics) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 42: Global: Statin (Others) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 43: Global: Statin (Others) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 44: North America: Statin Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 45: North America: Statin Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 46: United States: Statin Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 47: United States: Statin Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 48: Canada: Statin Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 49: Canada: Statin Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 50: Asia Pacific: Statin Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 51: Asia Pacific: Statin Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 52: China: Statin Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 53: China: Statin Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 54: Japan: Statin Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 55: Japan: Statin Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 56: India: Statin Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 57: India: Statin Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 58: South Korea: Statin Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 59: South Korea: Statin Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 60: Australia: Statin Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 61: Australia: Statin Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 62: Indonesia: Statin Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 63: Indonesia: Statin Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 64: Others: Statin Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 65: Others: Statin Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 66: Europe: Statin Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 67: Europe: Statin Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 68: Germany: Statin Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 69: Germany: Statin Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 70: France: Statin Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 71: France: Statin Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 72: United Kingdom: Statin Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 73: United Kingdom: Statin Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 74: Italy: Statin Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 75: Italy: Statin Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 76: Spain: Statin Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 77: Spain: Statin Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 78: Russia: Statin Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 79: Russia: Statin Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 80: Others: Statin Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 81: Others: Statin Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 82: Latin America: Statin Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 83: Latin America: Statin Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 84: Brazil: Statin Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 85: Brazil: Statin Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 86: Mexico: Statin Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 87: Mexico: Statin Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 88: Others: Statin Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 89: Others: Statin Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 90: Middle East and Africa: Statin Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 91: Middle East and Africa: Statin Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 92: Global: Statin Industry: SWOT Analysis
  • Figure 93: Global: Statin Industry: Value Chain Analysis
  • Figure 94: Global: Statin Industry: Porter's Five Forces Analysis

List of Tables

  • Table 1: Global: Statin Market: Key Industry Highlights, 2023 and 2032
  • Table 2: Global: Statin Market Forecast: Breakup by Type (in Million US$), 2024-2032
  • Table 3: Global: Statin Market Forecast: Breakup by Therapeutic Area (in Million US$), 2024-2032
  • Table 4: Global: Statin Market Forecast: Breakup by Drug Class (in Million US$), 2024-2032
  • Table 5: Global: Statin Market Forecast: Breakup by Application (in Million US$), 2024-2032
  • Table 6: Global: Statin Market Forecast: Breakup by Distribution (in Million US$), 2024-2032
  • Table 7: Global: Statin Market Forecast: Breakup by Region (in Million US$), 2024-2032
  • Table 8: Global: Statin Market: Competitive Structure
  • Table 9: Global: Statin Market: Key Players
目次
Product Code: SR112024A1885

The global statin market size reached US$ 15.4 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 20.0 Billion by 2032, exhibiting a growth rate (CAGR) of 2.9% during 2024-2032. The market is experiencing steady growth driven by the increasing prevalence of cardiovascular diseases and hypercholesterolemia globally, the expanding healthcare infrastructure and the availability of insurance coverage for cholesterol-lowering medications bolster demand across the globe.

Statin Market Analysis:

Market Growth and Size: The global market is experiencing significant growth, driven largely by the increasing prevalence of cardiovascular diseases. With the rising demand for cholesterol-lowering drugs, the market size is expanding, reflecting a growing awareness and need for effective treatments in managing heart health.

Technological Advancements: Technological developments, particularly in the field of personalized medicine, are revolutionizing the statin market. Advances in genomics and bioinformatics are enabling more personalized treatment approaches, improving the efficacy of statins and reducing the risk of adverse effects, thus propelling market growth.

Industry Applications: Statins are primarily used in the healthcare industry for the prevention and treatment of cardiovascular diseases by lowering LDL cholesterol levels. Their application has become integral in managing heart health, especially in populations with high risk of heart diseases.

Key Market Trends: A notable trend in the statin market is the shift towards precision medicine, where treatments are tailored to individual genetic profiles. Additionally, there is an increasing focus on preventive healthcare measures, which is driving the demand for statins as a preventive medication for cardiovascular diseases.

Geographical Trends: The demand for statins is particularly high in regions with aging populations and those with prevalent lifestyle-related risk factors for heart diseases. Developed regions such as North America and Europe currently dominate the market, but there is a growing demand in emerging economies due to increasing health awareness and improving healthcare infrastructure.

Competitive Landscape: The global market is characterized by the presence of several key players, with competition driven by innovation, product development, and marketing strategies. The market is also witnessing collaborations between pharmaceutical companies and healthcare providers to enhance the accessibility and effectiveness of statin therapy.

Challenges and Opportunities: One major challenge in the market is addressing the adverse effects associated with statin use, which can affect patient compliance. However, this challenge presents an opportunity for the development of new statin formulations with fewer side effects. Additionally, the increasing incidence of cardiovascular diseases globally offers a substantial opportunity for market expansion.

Statin Market Trends:

Increasing prevalence of cardiovascular diseases

The rising incidence of cardiovascular diseases (CVDs) majorly drives the global market. Statins, known for their cholesterol-lowering properties, play a critical role in the management and prevention of CVDs. This growing health burden is leading to a growing awareness and proactive management of risk factors such as high LDL cholesterol. Therefore, this is positively influencing the market. Consequently, the demand for statins is escalating, driven by both the increasing number of patients and the growing emphasis on preventive healthcare. This trend is particularly noticeable in regions with aging populations and lifestyle-related risk factors, making statins a key component in the treatment and management of cardiovascular health.

Advancements in personalized medicine

The global market is also being propelled forward by significant advancements in personalized medicine. Personalized, or precision, medicine involves tailoring medical treatment to the individual characteristics of each patient, and in the case of statins, this involves considering genetic factors that affect an individual's response to these drugs. Additionally, research has shown that genetic variations can influence a person's response to statins, both in terms of efficacy and risk of side effects. As a result, there is an increasing focus on developing personalized treatment plans that optimize statin therapy. In addition, the integration of genomics and bioinformatics in healthcare is thus a key factor driving innovation and growth in the market.

Government initiatives and healthcare policies

Government initiatives and healthcare policies significantly influence the global market. Many governments across the world are implementing policies and programs to combat the rising incidence of heart disease. These initiatives often include guidelines for cholesterol management, which recommend the use of statins as a first-line therapy. Moreover, governments and healthcare organizations are increasingly focusing on preventive healthcare measures, recognizing the cost-effectiveness of preventing heart diseases rather than treating them post-occurrence. This shift in focus is leading to increased funding for public health campaigns that raise awareness about the importance of cholesterol management, thereby driving the demand for statins. Additionally, the inclusion of statins in national and international treatment guidelines further underscores their importance in cardiovascular health management and boosts their adoption in clinical practice.

Statin Industry Segmentation:

IMARC Group provides an analysis of the key trends in each segment of the market, along with forecasts at the global, regional, and country levels for 2024-2032. Our report has categorized the market based on type, therapeutic area, drug class, application, and distribution.

Breakup by Type:

Synthetic Statins

Natural Statins

Natural statins account for the majority of the market share

The report has provided a detailed breakup and analysis of the statin market based on the type. This includes synthetic statins and natural statins. According to the report, natural statins represented the largest segment.

Breakup by Therapeutic Area:

Cardiovascular Disorders

Obesity

Inflammatory Disorders

Others

A detailed breakup and analysis of the statin market based on the therapeutic area has also been provided in the report. This includes cardiovascular disorders, obesity, inflammatory disorders, and others.

Breakup by Drug Class:

Atorvastatin

Fluvastatin

Lovastatin

Pravastatin

Simvastatin

Others

Atorvastatin represents the leading market segment

The report has provided a detailed breakup and analysis of the market based on the drug class. This includes atorvastatin, fluvastatin, lovastatin, pravastatin, simvastatin, and others. According to the report, atorvastatin accounted for the largest market share.

Breakup by Application:

Dyslipidemia

Others

A detailed breakup and analysis of the statin market based on the application has also been provided in the report. This includes dyslipidemia and others.

Breakup by Distribution:

Hospitals

Clinics

Others

Hospitals dominate the market

The report has provided a detailed breakup and analysis of the market based on the distribution. This includes hospitals, clinics, and others. According to the report, hospitals accounted for the largest market share.

Breakup by Region:

North America

United States

Canada

Asia Pacific

China

Japan

India

South Korea

Australia

Indonesia

Others

Europe

Germany

France

United Kingdom

Italy

Spain

Russia

Others

Latin America

Brazil

Mexico

Others

Middle East and Africa

North America leads the market, accounting for the largest statin market share

The market research report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Europe (Germany, France, the United Kingdom, Italy, Spain, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America accounted for the largest market share.

The market research report has provided a comprehensive analysis of the competitive landscape. Detailed profiles of all major companies have also been provided. Some of the key players in the market include:

AstraZeneca

Aurobindo Pharma

Biocon

GlaxoSmithKline

Merck & Co.

Novartis

Pfizer

Key Questions Answered in This Report

  • 1. What was the size of the global statin market in 2023?
  • 2. What is the expected growth rate of the global statin market during 2024-2032?
  • 3. What are the key factors driving the global statin market?
  • 4. What has been the impact of COVID-19 on the global statin market?
  • 5. What is the breakup of the global statin market based on the type?
  • 6. What is the breakup of the global statin market based on the drug class?
  • 7. What is the breakup of the global statin market based on the distribution?
  • 8. What are the key regions in the global statin market?
  • 9. Who are the key players/companies in the global statin market?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Statin Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Type

  • 6.1 Synthetic Statins
    • 6.1.1 Market Trends
    • 6.1.2 Market Forecast
  • 6.2 Natural Statins
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast

7 Market Breakup by Therapeutic Area

  • 7.1 Cardiovascular Disorders
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Obesity
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast
  • 7.3 Inflammatory Disorders
    • 7.3.1 Market Trends
    • 7.3.2 Market Forecast
  • 7.4 Others
    • 7.4.1 Market Trends
    • 7.4.2 Market Forecast

8 Market Breakup by Drug Class

  • 8.1 Atorvastatin
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2 Fluvastatin
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast
  • 8.3 Lovastatin
    • 8.3.1 Market Trends
    • 8.3.2 Market Forecast
  • 8.4 Pravastatin
    • 8.4.1 Market Trends
    • 8.4.2 Market Forecast
  • 8.5 Simvastatin
    • 8.5.1 Market Trends
    • 8.5.2 Market Forecast
  • 8.6 Others
    • 8.6.1 Market Trends
    • 8.6.2 Market Forecast

9 Market Breakup by Application

  • 9.1 Dyslipidemia
    • 9.1.1 Market Trends
    • 9.1.2 Market Forecast
  • 9.2 Others
    • 9.2.1 Market Trends
    • 9.2.2 Market Forecast

10 Market Breakup by Distribution

  • 10.1 Hospitals
    • 10.1.1 Market Trends
    • 10.1.2 Market Forecast
  • 10.2 Clinics
    • 10.2.1 Market Trends
    • 10.2.2 Market Forecast
  • 10.3 Others
    • 10.3.1 Market Trends
    • 10.3.2 Market Forecast

11 Market Breakup by Region

  • 11.1 North America
    • 11.1.1 United States
      • 11.1.1.1 Market Trends
      • 11.1.1.2 Market Forecast
    • 11.1.2 Canada
      • 11.1.2.1 Market Trends
      • 11.1.2.2 Market Forecast
  • 11.2 Europe
    • 11.2.1 Germany
      • 11.2.1.1 Market Trends
      • 11.2.1.2 Market Forecast
    • 11.2.2 France
      • 11.2.2.1 Market Trends
      • 11.2.2.2 Market Forecast
    • 11.2.3 United Kingdom
      • 11.2.3.1 Market Trends
      • 11.2.3.2 Market Forecast
    • 11.2.4 Italy
      • 11.2.4.1 Market Trends
      • 11.2.4.2 Market Forecast
    • 11.2.5 Spain
      • 11.2.5.1 Market Trends
      • 11.2.5.2 Market Forecast
    • 11.2.6 Russia
      • 11.2.6.1 Market Trends
      • 11.2.6.2 Market Forecast
    • 11.2.7 Others
      • 11.2.7.1 Market Trends
      • 11.2.7.2 Market Forecast
  • 11.3 Asia Pacific
    • 11.3.1 China
      • 11.3.1.1 Market Trends
      • 11.3.1.2 Market Forecast
    • 11.3.2 Japan
      • 11.3.2.1 Market Trends
      • 11.3.2.2 Market Forecast
    • 11.3.3 India
      • 11.3.3.1 Market Trends
      • 11.3.3.2 Market Forecast
    • 11.3.4 South Korea
      • 11.3.4.1 Market Trends
      • 11.3.4.2 Market Forecast
    • 11.3.5 Australia
      • 11.3.5.1 Market Trends
      • 11.3.5.2 Market Forecast
    • 11.3.6 Indonesia
      • 11.3.6.1 Market Trends
      • 11.3.6.2 Market Forecast
    • 11.3.7 Others
      • 11.3.7.1 Market Trends
      • 11.3.7.2 Market Forecast
  • 11.4 Latin America
    • 11.4.1 Brazil
      • 11.4.1.1 Market Trends
      • 11.4.1.2 Market Forecast
    • 11.4.2 Mexico
      • 11.4.2.1 Market Trends
      • 11.4.2.2 Market Forecast
    • 11.4.3 Others
      • 11.4.3.1 Market Trends
      • 11.4.3.2 Market Forecast
  • 11.5 Middle East and Africa
    • 11.5.1 Market Trends
    • 11.5.2 Market Breakup by Country
    • 11.5.3 Market Forecast

12 SWOT Analysis

  • 12.1 Overview
  • 12.2 Strengths
  • 12.3 Weaknesses
  • 12.4 Opportunities
  • 12.5 Threats

13 Value Chain Analysis

14 Porters Five Forces Analysis

  • 14.1 Overview
  • 14.2 Bargaining Power of Buyers
  • 14.3 Bargaining Power of Suppliers
  • 14.4 Degree of Competition
  • 14.5 Threat of New Entrants
  • 14.6 Threat of Substitutes

15 Price Indicators

16 Competitive Landscape

  • 16.1 Market Structure
  • 16.2 Key Players
  • 16.3 Profiles of Key Players
    • 16.3.1 Abbott
      • 16.3.1.1 Company Overview
      • 16.3.1.2 Product Portfolio
      • 16.3.1.3 Financials
      • 16.3.1.4 SWOT Analysis
    • 16.3.2 AstraZeneca
      • 16.3.2.1 Company Overview
      • 16.3.2.2 Product Portfolio
      • 16.3.2.3 Financials
      • 16.3.2.4 SWOT Analysis
    • 16.3.3 Aurobindo Pharma
      • 16.3.3.1 Company Overview
      • 16.3.3.2 Product Portfolio
      • 16.3.3.3 Financials
    • 16.3.4 Biocon
      • 16.3.4.1 Company Overview
      • 16.3.4.2 Product Portfolio
      • 16.3.4.3 Financials
      • 16.3.4.4 SWOT Analysis
    • 16.3.5 GlaxoSmithKline
      • 16.3.5.1 Company Overview
      • 16.3.5.2 Product Portfolio
      • 16.3.5.3 Financials
      • 16.3.5.4 SWOT Analysis
    • 16.3.6 Merck & Co.
      • 16.3.6.1 Company Overview
      • 16.3.6.2 Product Portfolio
      • 16.3.6.3 Financials
      • 16.3.6.4 SWOT Analysis
    • 16.3.7 Novartis
      • 16.3.7.1 Company Overview
      • 16.3.7.2 Product Portfolio
      • 16.3.7.3 Financials
      • 16.3.7.4 SWOT Analysis
    • 16.3.8 Pfizer
      • 16.3.8.1 Company Overview
      • 16.3.8.2 Product Portfolio
      • 16.3.8.3 Financials
      • 16.3.8.4 SWOT Analysis